<p>GoodRx Holdings, Inc.（纳斯达克代码：GDRX - 获取免费报告）的股票在目前覆盖该股票的十一家评级机构中获得了 “适度买入” 的平均推荐，MarketBeat 报道。四位研究分析师对该股票给予了持有推荐，六位分析师给予了买入推荐，还有一位分析师对该公司给予了强烈买入推荐。在过去一年中，发布报告的券商对该股票的平均一年目标价为 7.93 美元。</p>
<ul>
<li>Wegovy 与 Zepbound：谁赢得了 GLP-1 药物之战？</li>
</ul>
<p>几位分析师最近对该公司进行了评论。富国银行将 GoodRx 的目标价从 9.00 美元下调至 8.00 美元，并在 2 月 28 日的报告中对该公司给予了 “超配” 评级。花旗集团将 GoodRx 的目标价从 7.00 美元下调至 6.25 美元，并在 1 月 10 日的研究报告中对该公司给予了 “买入” 评级。KeyCorp 将 GoodRx 的目标价从 7.00 美元下调至 6.00 美元，并在 1 月 8 日的研究报告中对该股票给予了 “超配” 评级。最后，Truist Financial 将 GoodRx 的目标价从 6.50 美元下调至 5.50 美元，并在 4 月 10 日的研究报告中对该公司给予了 “持有” 评级。</p>
<p><strong>阅读我们关于 GDRX 的最新报告</strong></p>
<h2>机构投资者对 GoodRx 的看法</h2>
<ul>
<li>这只医疗保健股票引起了 160% 的增长热潮</li>
</ul>
<p>机构投资者最近买入和卖出了该公司的股票。巴克莱银行在第三季度将其在 GoodRx 的持股比例提高了 1,316.1%。巴克莱银行现在拥有 140,113 股该公司的股票，价值 973,000 美元，此前在上个季度又收购了 130,219 股。Geode Capital Management LLC 在第三季度将其在 GoodRx 的持股比例提高了 6.3%。Geode Capital Management LLC 现在拥有 982,729 股该公司的股票，价值 6,823,000 美元，此前在此期间又购买了 58,610 股。Sanctuary Advisors LLC 在第三季度购买了 GoodRx 的新头寸，价值约 85,000 美元。富兰克林资源公司在第三季度购买了 GoodRx 的新头寸，价值约 5,675,000 美元。最后，摩根大通在第三季度将其在 GoodRx 的持股比例提高了 358.7%。摩根大通现在拥有 24,293 股该公司的股票，价值 169,000 美元，此前在上个季度又购买了 18,997 股。对冲基金和其他机构投资者持有该公司 63.77% 的股票。</p>
<h2>GoodRx 股票下跌 2.5%</h2>
<p>纳斯达克：GDRX 周五开盘价为 4.68 美元。该公司的市值为 18 亿美元，市盈率为-156.00，市盈率增长比率为 2.46，贝塔系数为 1.25。该公司的流动比率为 5.48，速动比率为 5.48，债务与股本比率为 0.70。该公司的 50 日简单移动平均线为 4.58 美元，200 日简单移动平均线为 4.91 美元。GoodRx 的 12 个月低点为 3.82 美元，12 个月高点为 9.26 美元。</p>
<h2>关于 GoodRx</h2>
<p>（获取免费报告）</p>
<ul>
<li>基因疗法：为什么单次治疗要花费数百万？</li>
</ul>
<p>GoodRx Holdings, Inc.及其子公司提供信息和工具，使消费者能够比较价格并节省在美国的处方药购买费用。该公司运营一个价格比较平台，为消费者提供经过筛选的、地理相关的处方定价，以及获取谈判价格的途径。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票比 GoodRx 更好</li>
<li>股息筛选器：如何在购买前评估股息股票</li>
<li>空头最近放弃了这三只股票</li>
<li>找到并盈利交易 52 周低点的股票</li>
<li>今年表现优于市场的三只无聊股票</li>
<li>三只提供优厚股息收益的天然气股票</li>
<li>如果你想购买 AbbVie 而没有，现在仍然有时间购买</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0RSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0RSWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 GoodRx 吗？</h2>
<p>在考虑 GoodRx 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 GoodRx 并不在名单上。</p>
<p>虽然 GoodRx 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

GDRX

<p>GoodRx Holdings, Inc.（纳斯达克代码：GDRX）获得了十一位分析师的 “适度买入” 共识评级。平均一年期目标价为 7.93 美元，其中四位分析师建议持有，六位建议买入，一位建议强烈买入。最近的目标价调整包括：富国银行将其从 9.00 美元下调至 8.00 美元，花旗集团从 7.00 美元下调至 6.25 美元，KeyCorp 从 7.00 美元下调至 6.00 美元。该股票开盘价为 4.68 美元，市值为 18 亿美元，12 个月的价格区间为 3.82 美元至 9.26 美元</p>

<p>Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) have received an average recommendation of &#34;Moderate Buy&#34; from the eleven ratings firms that are presently covering the stock, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $7.93.</p>
<div class="lb-trans"><p>GoodRx Holdings, Inc.（纳斯达克代码：GDRX - 获取免费报告）的股票在目前覆盖该股票的十一家评级机构中获得了 “适度买入” 的平均推荐，MarketBeat 报道。四位研究分析师对该股票给予了持有推荐，六位分析师给予了买入推荐，还有一位分析师对该公司给予了强烈买入推荐。在过去一年中，发布报告的券商对该股票的平均一年目标价为 7.93 美元。</p>
</div><ul>
<li>Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?</li>
</ul>
<div class="lb-trans"><ul>
<li>Wegovy 与 Zepbound：谁赢得了 GLP-1 药物之战？</li>
</ul>
</div><p>Several analysts recently commented on the company. Wells Fargo &amp; Company cut their price objective on GoodRx from $9.00 to $8.00 and set an &#34;overweight&#34; rating for the company in a report on Friday, February 28th. Citigroup cut their price target on GoodRx from $7.00 to $6.25 and set a &#34;buy&#34; rating for the company in a research note on Friday, January 10th. KeyCorp lowered their price objective on shares of GoodRx from $7.00 to $6.00 and set an &#34;overweight&#34; rating on the stock in a research note on Wednesday, January 8th. Finally, Truist Financial cut their target price on shares of GoodRx from $6.50 to $5.50 and set a &#34;hold&#34; rating for the company in a research report on Thursday, April 10th.</p>
<div class="lb-trans"><p>几位分析师最近对该公司进行了评论。富国银行将 GoodRx 的目标价从 9.00 美元下调至 8.00 美元，并在 2 月 28 日的报告中对该公司给予了 “超配” 评级。花旗集团将 GoodRx 的目标价从 7.00 美元下调至 6.25 美元，并在 1 月 10 日的研究报告中对该公司给予了 “买入” 评级。KeyCorp 将 GoodRx 的目标价从 7.00 美元下调至 6.00 美元，并在 1 月 8 日的研究报告中对该股票给予了 “超配” 评级。最后，Truist Financial 将 GoodRx 的目标价从 6.50 美元下调至 5.50 美元，并在 4 月 10 日的研究报告中对该公司给予了 “持有” 评级。</p>
</div><p><strong>Read Our Latest Report on GDRX</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 GDRX 的最新报告</strong></p>
</div><h2>Institutional Investors Weigh In On GoodRx</h2>
<div class="lb-trans"><h2>机构投资者对 GoodRx 的看法</h2>
</div><ul>
<li>This healthcare stock making a buzz with 160% growth</li>
</ul>
<div class="lb-trans"><ul>
<li>这只医疗保健股票引起了 160% 的增长热潮</li>
</ul>
</div><p>Institutional investors have recently bought and sold shares of the business. Barclays PLC lifted its position in shares of GoodRx by 1,316.1% in the third quarter. Barclays PLC now owns 140,113 shares of the company's stock valued at $973,000 after acquiring an additional 130,219 shares in the last quarter. Geode Capital Management LLC raised its stake in GoodRx by 6.3% during the 3rd quarter. Geode Capital Management LLC now owns 982,729 shares of the company's stock valued at $6,823,000 after purchasing an additional 58,610 shares during the period. Sanctuary Advisors LLC purchased a new position in GoodRx in the 3rd quarter worth approximately $85,000. Franklin Resources Inc. bought a new position in GoodRx in the 3rd quarter worth approximately $5,675,000. Finally, JPMorgan Chase &amp; Co. grew its holdings in GoodRx by 358.7% during the 3rd quarter. JPMorgan Chase &amp; Co. now owns 24,293 shares of the company's stock valued at $169,000 after buying an additional 18,997 shares in the last quarter. Hedge funds and other institutional investors own 63.77% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近买入和卖出了该公司的股票。巴克莱银行在第三季度将其在 GoodRx 的持股比例提高了 1,316.1%。巴克莱银行现在拥有 140,113 股该公司的股票，价值 973,000 美元，此前在上个季度又收购了 130,219 股。Geode Capital Management LLC 在第三季度将其在 GoodRx 的持股比例提高了 6.3%。Geode Capital Management LLC 现在拥有 982,729 股该公司的股票，价值 6,823,000 美元，此前在此期间又购买了 58,610 股。Sanctuary Advisors LLC 在第三季度购买了 GoodRx 的新头寸，价值约 85,000 美元。富兰克林资源公司在第三季度购买了 GoodRx 的新头寸，价值约 5,675,000 美元。最后，摩根大通在第三季度将其在 GoodRx 的持股比例提高了 358.7%。摩根大通现在拥有 24,293 股该公司的股票，价值 169,000 美元，此前在上个季度又购买了 18,997 股。对冲基金和其他机构投资者持有该公司 63.77% 的股票。</p>
</div><h2>GoodRx Trading Down 2.5 %</h2>
<div class="lb-trans"><h2>GoodRx 股票下跌 2.5%</h2>
</div><p>NASDAQ:GDRX opened at $4.68 on Friday. The company has a market cap of $1.80 billion, a PE ratio of -156.00, a price-to-earnings-growth ratio of 2.46 and a beta of 1.25. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The company has a 50 day simple moving average of $4.58 and a two-hundred day simple moving average of $4.91. GoodRx has a 12 month low of $3.82 and a 12 month high of $9.26.</p>
<div class="lb-trans"><p>纳斯达克：GDRX 周五开盘价为 4.68 美元。该公司的市值为 18 亿美元，市盈率为-156.00，市盈率增长比率为 2.46，贝塔系数为 1.25。该公司的流动比率为 5.48，速动比率为 5.48，债务与股本比率为 0.70。该公司的 50 日简单移动平均线为 4.58 美元，200 日简单移动平均线为 4.91 美元。GoodRx 的 12 个月低点为 3.82 美元，12 个月高点为 9.26 美元。</p>
</div><h2>About GoodRx</h2>
<div class="lb-trans"><h2>关于 GoodRx</h2>
</div><p>(Get Free Report</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><ul>
<li>Gene therapy: Why does it cost millions for a single treatment?</li>
</ul>
<div class="lb-trans"><ul>
<li>基因疗法：为什么单次治疗要花费数百万？</li>
</ul>
</div><p>GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.</p>
<div class="lb-trans"><p>GoodRx Holdings, Inc.及其子公司提供信息和工具，使消费者能够比较价格并节省在美国的处方药购买费用。该公司运营一个价格比较平台，为消费者提供经过筛选的、地理相关的处方定价，以及获取谈判价格的途径。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than GoodRx</li>
<li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li>
<li>Short Sellers Gave Up on These 3 Names Recently</li>
<li>Find and Profitably Trade Stocks at 52-Week Lows</li>
<li>3 Boring Stocks Outperforming the Market This Year</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 GoodRx 更好</li>
<li>股息筛选器：如何在购买前评估股息股票</li>
<li>空头最近放弃了这三只股票</li>
<li>找到并盈利交易 52 周低点的股票</li>
<li>今年表现优于市场的三只无聊股票</li>
<li>三只提供优厚股息收益的天然气股票</li>
<li>如果你想购买 AbbVie 而没有，现在仍然有时间购买</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0RSWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=GDRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in GoodRx Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 GoodRx 吗？</h2>
</div><p>Before you consider GoodRx, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 GoodRx 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 GoodRx 并不在名单上。</p>
</div><p>While GoodRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 GoodRx 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

GoodRx Holdings, Inc.（NASDAQ:GDRX）被分析师一致评级为 “适度买入”